Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial ID NCT02338232

Rank	Title	Journal	Year	PubWeight™‹?›
101	Comparative effects of telmisartan in the treatment of hypertension.	J Clin Hypertens (Greenwich)	2002	0.77
102	Rosiglitazone prevents graft-versus-host disease (GVHD).	Transpl Immunol	2012	0.77
103	Rho-kinase inhibitors decrease TGF-beta-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts.	Biochem Pharmacol	2008	0.77
104	Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation.	PLoS One	2013	0.76
105	Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.	Arterioscler Thromb Vasc Biol	2013	0.76
106	The prognostic values of leukocyte Rho kinase activity in acute ischemic stroke.	Biomed Res Int	2014	0.76
107	Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.	Blood Press	2013	0.75
108	Targeting neovascularization in GVHD.	Blood	2013	0.75